BioNexus Gene Lab (BGLC) Cash & Equivalents (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Cash & Equivalents data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 35.98% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 35.98% YoY), and the FY2025 full-year result was $2.4 million, down 17.44% from the prior year.
• Cash & Equivalents eased to $1.3 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $5.8 million in Q1 2024 to a low of $814179.0 in Q2 2025.
• A 5-year average of $2.5 million and a median of $2.1 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 221.75% in 2023 and slumped 79.45% in 2025, its largest moves.
• Tracing BGLC's Cash & Equivalents over 5 years: stood at $2.1 million in 2022, then surged by 113.21% to $4.5 million in 2023, then sank by 36.1% to $2.9 million in 2024, then fell by 17.44% to $2.4 million in 2025, then sank by 43.88% to $1.3 million in 2026.
• Business Quant data shows BGLC's Cash & Equivalents at $1.3 million in Q1 2026, $2.4 million in Q4 2025, and $1.2 million in Q3 2025.